US5586226A
(en)
*
|
1990-05-16 |
1996-12-17 |
Canon Kabushiki Kaisha |
Control method and device for a unicolor printer
|
US5912410A
(en)
*
|
1990-06-15 |
1999-06-15 |
Scios Inc. |
Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease
|
ES2335720T3
(es)
*
|
1991-01-21 |
2010-03-31 |
Elan Pharmaceuticals, Inc. |
Ensayo y modelo para la enfermedad de alzheimer.
|
ES2204899T3
(es)
*
|
1992-01-07 |
2004-05-01 |
Elan Pharmaceuticals, Inc. |
Modelos de animales transgenicos para la enfermedad de alzheimer.
|
US6610493B1
(en)
|
1993-06-17 |
2003-08-26 |
Brigham And Women's Hospital |
Screening compounds for the ability to alter the production of amyloid-β peptide
|
US6264915B1
(en)
|
1992-09-13 |
2001-07-24 |
The President And Fellows Of Harvard College |
Process for detecting potential carcinogens
|
AU5684594A
(en)
*
|
1992-12-02 |
1994-06-22 |
Novo Nordisk A/S |
Novel human amyloid protein precursor homologue and kunitz-type inhibitors
|
US5436153A
(en)
*
|
1992-12-02 |
1995-07-25 |
Sprecher; Cindy A. |
Human amyloid protein precursor homolog and Kunitz-type inhibitor
|
AU702293B2
(en)
|
1993-10-27 |
1999-02-18 |
Athena Neurosciences, Inc. |
Transgenic animals harboring APP allele having Swedish mutation
|
JPH07132033A
(ja)
*
|
1993-11-12 |
1995-05-23 |
Hoechst Japan Ltd |
アルツハイマー病モデルトランスジェニック動物
|
EP0742831B1
(en)
|
1994-01-27 |
2004-09-29 |
The Regents Of The University Of Minnesota |
Transgenic non-human mammals with progressive neurologic disease
|
US5877399A
(en)
*
|
1994-01-27 |
1999-03-02 |
Johns Hopkins University |
Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
|
FR2716460B1
(fr)
*
|
1994-02-21 |
2002-08-09 |
Rhone Poulenc Rorer Sa |
Modèle animal de la maladie d'Alzheimer, préparation et utilisations.
|
US6025183A
(en)
*
|
1994-02-28 |
2000-02-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Transgenic animal assay system for anti-cholinesterase substances
|
AU2635295A
(en)
*
|
1994-06-13 |
1996-01-05 |
Henry Ford Health System |
A novel neuronal-neonatal gene: neuronatin
|
WO1996006927A1
(en)
*
|
1994-09-01 |
1996-03-07 |
Merck & Co., Inc. |
Transgenic animal expressing a familial form of human amyloid precursor protein
|
US6114133A
(en)
*
|
1994-11-14 |
2000-09-05 |
Elan Pharmaceuticals, Inc. |
Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
|
US7427392B1
(en)
|
1994-11-14 |
2008-09-23 |
Elan Pharmaceuticals, Inc. |
Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
|
US6187992B1
(en)
|
1994-12-05 |
2001-02-13 |
Merck & Co., Inc. |
Transgenic mouse having a disrupted amyloid precursor protein gene
|
EP0799305A4
(en)
*
|
1994-12-05 |
2000-01-26 |
Merck & Co Inc |
TRANSGENIC ANIMAL WITH NATIVE AMYLOID PRECURSOR PROTEIN DEFICIENCY
|
US5777194A
(en)
*
|
1995-04-26 |
1998-07-07 |
Cephalon, Inc. |
Gene-targeted mice with humanized Aβ sequence and Swedish FAD mutation
|
US5777093A
(en)
*
|
1995-05-16 |
1998-07-07 |
Ramot-University Authority For Applied Research & Industrial Development Ltd. |
cDNAs associated with ataxia-telangiectasia
|
US5858661A
(en)
*
|
1995-05-16 |
1999-01-12 |
Ramot-University Authority For Applied Research And Industrial Development |
Ataxia-telangiectasia gene and its genomic organization
|
US5728807A
(en)
*
|
1995-05-16 |
1998-03-17 |
Ramot-University Authority For Applied Research And Industrial Development, Ltd. |
Mutated proteins associated with ataxia-telangiectasia
|
US6187991B1
(en)
|
1995-05-23 |
2001-02-13 |
Pfizer Inc |
Transgenic animal models for type II diabetes mellitus
|
US6717031B2
(en)
|
1995-06-07 |
2004-04-06 |
Kate Dora Games |
Method for selecting a transgenic mouse model of alzheimer's disease
|
EP0833901A1
(en)
*
|
1995-06-07 |
1998-04-08 |
Athena Neurosciences, Inc. |
Method for identifying alzheimer's disease therapeutics using transgenic animal models
|
WO1996040895A1
(en)
*
|
1995-06-07 |
1996-12-19 |
Athena Neurosciences, Inc. |
Method for identifying alzheimer's disease therapeutics using transgenic animal models
|
US5894078A
(en)
*
|
1996-02-26 |
1999-04-13 |
Advanced Bioconcept, Inc. |
Transgenic mouse expressing C-100 app
|
US6140309A
(en)
*
|
1996-03-12 |
2000-10-31 |
University Of South Florida |
Vasoactive effects and free radical generation by β-amyloid peptides
|
AU3640297A
(en)
*
|
1996-06-06 |
1998-01-05 |
University Of Washington |
Perlecan transgenic animals and methods of identifying compounds for the treatment of amyloidoses
|
CA2259123C
(en)
|
1996-07-01 |
2003-10-21 |
Jim A. Wright |
Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth
|
US20010016951A1
(en)
|
1996-07-24 |
2001-08-23 |
Bernd Sommer |
Transgenic animal model for alzheimer disease
|
WO1998003643A2
(en)
*
|
1996-07-22 |
1998-01-29 |
Smithkline Beecham Pharma Gmbh |
Transgenic animals with mutant human app or a4ct sequences
|
AU718473B2
(en)
*
|
1996-07-24 |
2000-04-13 |
Novartis Ag |
Transgenic animal model for alzheimer disease
|
JP2000517185A
(ja)
|
1996-08-29 |
2000-12-26 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
新規なメタロプロテアーゼファミリーkuz
|
US6566089B1
(en)
*
|
1996-09-04 |
2003-05-20 |
Tularik Inc. |
Cell-based drug screens for regulators of gene expression
|
AU4867097A
(en)
*
|
1996-10-10 |
1998-05-05 |
Institut Pasteur |
Transgenic or mutated animal as model for a neuron deficit
|
US5898094A
(en)
*
|
1996-10-21 |
1999-04-27 |
University Of South Florida |
Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
|
US7973156B2
(en)
|
1997-08-21 |
2011-07-05 |
Quark Pharmaceuticals Inc. |
Hypoxia-regulated genes
|
US6905686B1
(en)
|
1997-12-02 |
2005-06-14 |
Neuralab Limited |
Active immunization for treatment of alzheimer's disease
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
US6710226B1
(en)
|
1997-12-02 |
2004-03-23 |
Neuralab Limited |
Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
|
US6750324B1
(en)
|
1997-12-02 |
2004-06-15 |
Neuralab Limited |
Humanized and chimeric N-terminal amyloid beta-antibodies
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
US6787523B1
(en)
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
JP4652566B2
(ja)
|
1998-01-12 |
2011-03-16 |
ロビン・エイ・フェルダー |
本態性高血圧症におけるgタンパク質関連変異体
|
WO1999043697A1
(en)
*
|
1998-02-25 |
1999-09-02 |
The Board Of Regents Of The University And Community College System Of Nevada On Behalf Of The University Of Nevada-Reno |
Manganese superoxide dismutase exon 3-deleted isoforms and nucleic acid molecules encoding the isoforms
|
US20030147882A1
(en)
|
1998-05-21 |
2003-08-07 |
Alan Solomon |
Methods for amyloid removal using anti-amyloid antibodies
|
US6548261B1
(en)
|
1998-12-30 |
2003-04-15 |
Case Western Reserve University |
Alzheimer model for drug screening
|
EP1026251A3
(en)
*
|
1999-02-03 |
2000-09-06 |
Pfizer Products Inc. |
Transgenic animals expressing human P25
|
US6374130B1
(en)
|
1999-04-06 |
2002-04-16 |
Eric M. Reiman |
Methods for tracking the progression of Alzheimer's disease identifying treatment using transgenic mice
|
US6670195B1
(en)
|
1999-05-26 |
2003-12-30 |
New York University |
Mutant genes in Familial British Dementia and Familial Danish Dementia
|
US6787637B1
(en)
|
1999-05-28 |
2004-09-07 |
Neuralab Limited |
N-Terminal amyloid-β antibodies
|
US6787318B1
(en)
|
1999-06-01 |
2004-09-07 |
Roskamp Research Institute, Llc |
Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
|
UA81216C2
(en)
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
US6541244B1
(en)
*
|
1999-06-07 |
2003-04-01 |
Cedars-Sinai Medical Center |
Suppressor of cytokine signaling (SOCS)-3 promoter and methods for its use in genetic therapy in humans
|
AU5602100A
(en)
|
1999-06-09 |
2000-12-28 |
Arch Development Corporation |
Recombinant prion-like genes and proteins and materials and methods comprising same
|
US6875582B1
(en)
|
1999-08-19 |
2005-04-05 |
Omniscience Pharmaceuticals, Inc. |
Methods and targets of antibiotic resistance
|
US6864355B1
(en)
|
2000-05-02 |
2005-03-08 |
Yale University |
Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
|
US6762029B2
(en)
|
1999-12-23 |
2004-07-13 |
Portola Pharmaceuticals, Inc. |
Methods of identifying agents that modulate P2Y12 receptor activity
|
HUP0203863A3
(en)
|
2000-01-12 |
2008-03-28 |
Univ Yale |
Nogo receptor-mediated blockade of axonal growth
|
AU2001225441A1
(en)
|
2000-01-24 |
2001-07-31 |
Agricultural Research Organization The Volcani Center |
Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
|
US6982361B1
(en)
*
|
2000-02-25 |
2006-01-03 |
The Regents Of The University Of California |
Method of screening a compound for anxiolytic activity in an Apolipoprotein e knockout animal
|
US6992081B2
(en)
|
2000-03-23 |
2006-01-31 |
Elan Pharmaceuticals, Inc. |
Compounds to treat Alzheimer's disease
|
DE60124080T2
(de)
|
2000-03-23 |
2007-03-01 |
Elan Pharmaceuticals, Inc., San Francisco |
Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
|
AU2001266557A1
(en)
|
2000-04-12 |
2001-10-23 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
PE20020276A1
(es)
|
2000-06-30 |
2002-04-06 |
Elan Pharm Inc |
COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
|
EP1666452A2
(en)
|
2000-06-30 |
2006-06-07 |
Elan Pharmaceuticals, Inc. |
Compounds to treat Alzheimer's disease
|
EP1299352B1
(en)
|
2000-06-30 |
2005-12-28 |
Elan Pharmaceuticals, Inc. |
Compounds to treat alzheimer's disease
|
US6846813B2
(en)
*
|
2000-06-30 |
2005-01-25 |
Pharmacia & Upjohn Company |
Compounds to treat alzheimer's disease
|
US20030096864A1
(en)
*
|
2000-06-30 |
2003-05-22 |
Fang Lawrence Y. |
Compounds to treat alzheimer's disease
|
HUP0300810A2
(hu)
|
2000-07-20 |
2003-08-28 |
M.G.V.S. Ltd. |
Mesterséges értranszplantátum, valamint ennek létrehozása és alkalmazása
|
US20040037828A1
(en)
|
2002-07-09 |
2004-02-26 |
Bar-Ilan University |
Methods and pharmaceutical compositions for healing wounds
|
US20050239125A1
(en)
*
|
2000-09-06 |
2005-10-27 |
Hodge Timothy A |
Methods for genotype screening
|
US7494817B2
(en)
*
|
2000-09-06 |
2009-02-24 |
Transnet Yx, Inc. |
Methods for genotype screening using magnetic particles
|
US20030087286A1
(en)
*
|
2000-09-06 |
2003-05-08 |
Hodge Timothy A. |
Isolation of eukaryotic genomic DNA using magnetically responsive solid functionalized particles
|
US20050266494A1
(en)
*
|
2000-09-06 |
2005-12-01 |
Hodge Timothy A |
System and method for computer network ordering of biological testing
|
US7011943B2
(en)
|
2000-09-06 |
2006-03-14 |
Transnetyx, Inc. |
Method for detecting a designated genetic sequence in murine genomic DNA
|
US20030082605A1
(en)
*
|
2000-09-06 |
2003-05-01 |
Hodge Timothy A. |
Genomic DNA detection method and system thereof
|
US20050272085A1
(en)
*
|
2000-09-06 |
2005-12-08 |
Hodge Timothy A |
Methods for forensic and congenic screening
|
US6900367B2
(en)
*
|
2000-09-29 |
2005-05-31 |
Novartis |
Transgenic Drosophila melanogaster expressing a β42 in the eye
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
US20020170078A1
(en)
*
|
2001-03-08 |
2002-11-14 |
Isabelle Mansuy |
Calcineurin-related transgenic mammals, compositions and methods
|
US7081561B2
(en)
|
2001-03-16 |
2006-07-25 |
The Regents Of The University Of California |
Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof
|
BR0210122A
(pt)
*
|
2001-06-01 |
2004-06-15 |
Elan Pharm Inc |
Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
|
CA2450205A1
(en)
|
2001-06-13 |
2002-12-19 |
Elan Pharmaceuticals, Inc. |
Aminediols for the treatment of alzheimer's disease
|
CA2452039A1
(en)
*
|
2001-06-27 |
2003-01-09 |
Elan Pharmaceuticals, Inc. |
Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
|
US20070213407A1
(en)
*
|
2001-06-29 |
2007-09-13 |
Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc |
Compounds to treat Alzheimer's disease
|
MXPA04000338A
(es)
*
|
2001-07-10 |
2004-07-23 |
Upjohn Co |
Diamindioles para tratamiento de enfermedad de alzheimer.
|
MXPA04000337A
(es)
*
|
2001-07-10 |
2004-07-23 |
Upjohn Co |
Amindioles para tratamiento de enfermedad de alzheimer.
|
US7297553B2
(en)
*
|
2002-05-28 |
2007-11-20 |
Nanosphere, Inc. |
Method for attachment of silylated molecules to glass surfaces
|
CA2455497A1
(en)
*
|
2001-08-31 |
2003-03-06 |
Neurochem (International) Limited |
Amidine derivatives for treating amyloidosis
|
US20060014186A1
(en)
*
|
2001-09-04 |
2006-01-19 |
Hodge Timothy A |
Methods for genotype screening of a strain disposed on an adsorbent carrier
|
AU2002343483A1
(en)
|
2001-10-04 |
2003-04-14 |
Elan Pharmaceuticals, Inc. |
Hydroxypropylamines
|
JP2005520791A
(ja)
*
|
2001-11-08 |
2005-07-14 |
イーラン ファーマスーティカルズ、インコーポレイテッド |
N,n’−置換−1,3−ジアミノ−2−ヒドロキシプロパン誘導体
|
CA2467476A1
(en)
*
|
2001-11-19 |
2003-05-30 |
Pharmacia & Upjohn Company |
Amino diols useful in the treatment of alzheimer's disease
|
WO2003048298A2
(en)
|
2001-12-05 |
2003-06-12 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Nanoparticles containing polymeric nucleic acid homologs, pharmaceutical compositions and articles of manufacture containing same and methods of use thereof
|
EP2990417A1
(en)
|
2001-12-21 |
2016-03-02 |
Human Genome Sciences, Inc. |
Albumin insulin fusion protein
|
US6992176B2
(en)
|
2002-02-13 |
2006-01-31 |
Technion Research & Development Foundation Ltd. |
Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
|
AU2003216370A1
(en)
*
|
2002-02-27 |
2003-09-09 |
Merck And Co., Inc. |
Assays to monitor amyloid precursor protein processing
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
WO2004058686A1
(en)
*
|
2002-04-30 |
2004-07-15 |
Elan Pharmaceuticals, Inc. |
Hydroxypropyl amides for the treatment of alzheimer’s disease
|
UY27967A1
(es)
*
|
2002-09-10 |
2004-05-31 |
Pfizer |
Acetil 2-hindroxi-1,3-diaminoalcanos
|
JP2006512923A
(ja)
|
2002-10-18 |
2006-04-20 |
エルジー ライフサイエンス リミテッド |
癌関連遺伝子ファミリー
|
AU2003293155A1
(en)
|
2002-11-27 |
2004-06-23 |
Elan Pharmaceutical, Inc. |
Substituted ureas and carbamates
|
US7341847B2
(en)
*
|
2003-04-02 |
2008-03-11 |
Agency For Science, Technology And Research |
Promoter construct for gene expression in neuronal cells
|
CL2004000849A1
(es)
*
|
2003-04-21 |
2005-01-28 |
Elan Pharmaceuticals Inc Pharm |
Compuestos derivados de benzamidas-2-hidroxi-3-diaminoalcanos, utiles para el tratamiento o la prevencion de alzheimer, sindrome de down, hemorragia cerebral hereditaria, demencias degenerativas y otras.
|
MXPA05011203A
(es)
*
|
2003-04-21 |
2005-12-15 |
Elan Pharm Inc |
Fenacil-2-hidroxi-3-diaminoalcanos.
|
IL155666A
(en)
*
|
2003-04-29 |
2013-12-31 |
Neurim Pharma 1991 |
Insomnia treatment
|
AU2004247013B2
(en)
*
|
2003-05-14 |
2010-07-08 |
Neurogenetic Pharmaceuticals, Inc. |
Compounds and uses thereof in modulating amyloid beta
|
CA2526900C
(en)
|
2003-05-19 |
2015-11-24 |
Elan Pharmaceuticals, Inc. |
Truncated fragments of alpha-synuclein in lewy body disease
|
US7358331B2
(en)
|
2003-05-19 |
2008-04-15 |
Elan Pharmaceuticals, Inc. |
Truncated fragments of alpha-synuclein in Lewy body disease
|
TWI306458B
(en)
|
2003-05-30 |
2009-02-21 |
Elan Pharma Int Ltd |
Humanized antibodies that recognize beta amyloid peptide
|
EP1729755A1
(en)
*
|
2004-01-21 |
2006-12-13 |
Elan Pharmaceuticals, Inc. |
Methods of treatment of amyloidosis using aspartyl-protease inihibitors
|
US7262223B2
(en)
*
|
2004-01-23 |
2007-08-28 |
Neurochem (International) Limited |
Amidine derivatives for treating amyloidosis
|
JP2007528400A
(ja)
*
|
2004-03-09 |
2007-10-11 |
エラン ファーマシューティカルズ,インコーポレイテッド |
置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
|
WO2005087215A1
(en)
|
2004-03-09 |
2005-09-22 |
Elan Pharmaceuticals, Inc. |
Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
|
US20050239832A1
(en)
*
|
2004-03-09 |
2005-10-27 |
Varghese John |
Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
|
EP1735293A2
(en)
*
|
2004-03-09 |
2006-12-27 |
Elan Pharmaceuticals, Inc. |
Substituted hydroxyethylamine aspartyl protease inhibitors
|
SE0400707D0
(sv)
|
2004-03-22 |
2004-03-22 |
Bioarctic Neuroscience Ab |
Transgenic animal model
|
KR100574544B1
(ko)
*
|
2004-04-01 |
2006-04-27 |
주식회사 뉴로테크 |
돌연변이 βCTF99를 발현하는 알츠하이머병 유발형질전환 마우스
|
US7544855B2
(en)
*
|
2004-04-23 |
2009-06-09 |
Buck Institute |
Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
|
EP1750719A2
(en)
*
|
2004-05-19 |
2007-02-14 |
Boehringer Ingelheim International GmbH |
Treatment of diseases associated with altered level of amyloid beta peptides
|
JP4476050B2
(ja)
*
|
2004-06-30 |
2010-06-09 |
株式会社ニデック |
視野計
|
US7385085B2
(en)
*
|
2004-07-09 |
2008-06-10 |
Elan Pharmaceuticals, Inc. |
Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
|
US20060128715A1
(en)
*
|
2004-07-09 |
2006-06-15 |
Jennifer Sealy |
Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
|
US8383637B2
(en)
*
|
2004-08-06 |
2013-02-26 |
Jansssen Pharmaceutica N.V. |
2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
|
US8426429B2
(en)
*
|
2004-08-06 |
2013-04-23 |
Jansssen Pharmaceutica N.V. |
2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
|
US8436006B2
(en)
*
|
2004-08-06 |
2013-05-07 |
Jansssen Pharmaceutica N.V. |
2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
|
GB0419124D0
(en)
*
|
2004-08-27 |
2004-09-29 |
Proteome Sciences Plc |
Methods and compositions relating to Alzheimer's disease
|
JP2008511644A
(ja)
*
|
2004-08-27 |
2008-04-17 |
エラン ファーマシューティカルズ,インコーポレイテッド |
エタノール環式アミンアスパラギン酸プロテアーゼ阻害剤を用いて、アミロイドーシスを治療する方法
|
US7833513B2
(en)
|
2004-12-03 |
2010-11-16 |
Rhode Island Hospital |
Treatment of Alzheimer's Disease
|
TW200635607A
(en)
|
2004-12-15 |
2006-10-16 |
Elan Pharm Inc |
Humanized Aβ antibodies for use in improving cognition
|
CA2597945C
(en)
|
2005-02-17 |
2016-07-12 |
Biogen Idec Ma Inc. |
Treating neurological disorders
|
EP1746092A1
(en)
|
2005-07-22 |
2007-01-24 |
Exonhit Therapeutics SA |
Compounds and methods for treatment of amyloid-B-peptide related disorders
|
EP1913017A1
(en)
*
|
2005-08-03 |
2008-04-23 |
Boehringer Ingelheim International GmbH |
Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii
|
EP1915353A2
(de)
*
|
2005-08-11 |
2008-04-30 |
Boehringer Ingelheim International GmbH |
Isophthalsäurediamide zur behandlung der alzheimer erkrankung
|
US20090042867A1
(en)
*
|
2005-08-11 |
2009-02-12 |
Klaus Fuchs |
Compounds for the treatment of alzheimer's disease
|
CA2618481A1
(en)
*
|
2005-08-11 |
2007-02-15 |
Boehringer Ingelheim International Gmbh |
Compounds for treating alzheimer's disease
|
EP1915339A1
(de)
*
|
2005-08-11 |
2008-04-30 |
Boehringer Ingelheim International GmbH |
Inhibitoren der beta-sekretase zur behandlung der alzheimer- erkrankung
|
WO2007047305A1
(en)
*
|
2005-10-12 |
2007-04-26 |
Elan Pharmaceuticals, Inc. |
Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
|
EP1937638A1
(en)
*
|
2005-10-12 |
2008-07-02 |
Elan Pharmaceuticals Inc. |
Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors
|
JP2009525110A
(ja)
|
2006-01-31 |
2009-07-09 |
マルチ ジーン バスキュラー システムズ, インコーポレイテッド |
薬物溶出血管内プロテーゼおよび使用方法
|
WO2007092854A2
(en)
*
|
2006-02-06 |
2007-08-16 |
Janssen Pharmaceutica N.V. |
2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
|
WO2007092839A2
(en)
*
|
2006-02-06 |
2007-08-16 |
Janssen Pharmaceutica N.V. |
Macrocycle derivatives useful as inhibitors of beta-secretase (bace)
|
US7776882B2
(en)
*
|
2006-02-06 |
2010-08-17 |
Baxter Ellen W |
2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE)
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
US9505823B2
(en)
*
|
2006-08-07 |
2016-11-29 |
TEV A Biopharmaceuticals USA, Inc. |
Albumin-insulin fusion proteins
|
US8454948B2
(en)
|
2006-09-14 |
2013-06-04 |
Medgenics Medical Israel Ltd. |
Long lasting drug formulations
|
US9127084B2
(en)
|
2006-09-14 |
2015-09-08 |
Medgenics Medical Israel Ltd. |
Long lasting drug formulations
|
CA2664318C
(en)
|
2006-09-14 |
2017-05-23 |
Andrew L. Pearlman |
Long lasting drug formulations
|
JP5607930B2
(ja)
|
2006-10-12 |
2014-10-15 |
ビーエイチアイ リミテッド パートナーシップ |
3−アミノ−1−プロパンスルホン酸を送達するための方法、化合物、組成物および媒体
|
PL381605A1
(pl)
|
2007-01-25 |
2008-08-04 |
Instytut Biologii Doświadczalnej Im. M. Nenckiego Polskiej Akadmii Nauk |
Transgeniczne zwierzę i sposób jego otrzymywania
|
EP2134863B1
(en)
|
2007-03-13 |
2014-05-21 |
The Children's Hospital Of Philadelphia |
Genetic alterations on chromosome 16 and methods of use thereof for the diagnosis of type 1 diabetes
|
US7943590B2
(en)
|
2007-03-16 |
2011-05-17 |
Multi-Gene Vascular Systems Ltd. |
Compositions and methods for treating ophthalmic disorders
|
EP2514766A3
(en)
|
2007-03-29 |
2013-06-05 |
Technion Research & Development Foundation Ltd. |
Antibodies, methods and kits for diagnosing and treating melanoma
|
DK2623605T3
(da)
|
2007-04-09 |
2019-03-25 |
Univ Florida |
Raav-vektorsammensætninger med tyrosinmodificerede capsidproteiner og fremgangsmåder til anvendelse deraf
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
US8222264B2
(en)
|
2007-07-06 |
2012-07-17 |
Boehringer Ingelheim International Gmbh |
Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
|
ES2498040T3
(es)
|
2007-07-27 |
2014-09-24 |
Janssen Alzheimer Immunotherapy |
Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
EP2238111B1
(en)
*
|
2008-01-28 |
2013-01-16 |
Janssen Pharmaceutica NV |
6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of -secretase (bace)
|
RU2010136050A
(ru)
*
|
2008-01-29 |
2012-03-10 |
Янссен Фармацевтика Нв (Be) |
2-аминохинолиновые производные для использования в качестве ингибиторов секретазы (васе)
|
EP2257643B1
(en)
|
2008-02-19 |
2015-04-08 |
The Children's Hospital Of Philadelphia |
Identification of pediatric onset inflammatory bowel disease loci and methods of use thereof for the diagnosis and treatment of the same
|
EP2116260A1
(en)
*
|
2008-04-16 |
2009-11-11 |
Freie Universität Berlin |
Screening method for agents suitable for prophylaxis and therapy of Alzheimer's disease (AD)
|
JP6095889B2
(ja)
|
2008-05-16 |
2017-03-15 |
ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia |
染色体21q、6q、および15qの遺伝子変異およびこれらを使用して1型糖尿病を診断および治療する方法
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
US20110023152A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genome editing of cognition related genes in animals
|
EP2499282B1
(en)
|
2009-11-09 |
2015-04-22 |
NeuroGenetic Pharmaceuticals, Inc. |
Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
|
CA2796399C
(en)
|
2010-04-23 |
2021-08-24 |
Shannon Elizabeth Boye |
Raav-guanylate cyclase compositions and methods for treating leber congenital amaurosis-1 (lca1)
|
DK2605655T3
(da)
|
2010-08-19 |
2019-02-04 |
Buck Institute For Age Res |
Fremgangsmåder til behandling af let kognitiv svækkelse (mci) og relaterede forstyrrelser
|
EP3607946B1
(en)
|
2012-03-19 |
2023-02-22 |
Buck Institute for Research on Aging |
App specific bace inhibitors (asbis) and uses thereof
|
ES2975235T3
(es)
|
2013-02-12 |
2024-07-04 |
Buck Inst Res Aging |
Hidantoínas que modulan el procesamiento de APP mediado por BACE
|
US20150118187A1
(en)
|
2013-10-24 |
2015-04-30 |
Medgenics Medical Israel Ltd. |
Micro-organs providing sustained delivery of a therapeutic polypeptide and methods of use thereof
|
WO2016077078A1
(en)
|
2014-10-29 |
2016-05-19 |
The Children's Hospital Of Philadelphia |
Diagnosis and treatment of genetic alterations associated with eosinophilic esophagitis
|
EP3224380A1
(en)
|
2014-11-25 |
2017-10-04 |
The Broad Institute Inc. |
Clonal haematopoiesis
|
WO2016086197A1
(en)
|
2014-11-25 |
2016-06-02 |
The Brigham And Women's Hospital, Inc. |
Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease
|
AU2016313506A1
(en)
|
2015-08-21 |
2018-03-08 |
The Children's Hospital Of Philadelphia |
Methods of treating autoimmune conditions in patients with genetic variations in DcR3 or in a DcR3 network gene
|
KR20180090778A
(ko)
|
2015-08-27 |
2018-08-13 |
난트뉴로, 엘엘씨 |
App-선택적 bace 억제를 위한 조성물 및 그의 용도
|
JP7027341B2
(ja)
|
2016-05-12 |
2022-03-01 |
バック・インスティテュート・フォー・リサーチ・オン・エイジング |
Appの正常なプロセシングを促進する化合物
|
KR20220109346A
(ko)
*
|
2021-01-28 |
2022-08-04 |
주식회사 에이브레인 |
신경 퇴행성 질환의 치료를 위한 유전자 요법
|